SCHEMBL3917563

SCHEMBL3917563

NC(=CC(=O)O)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 2/20 0.52
CES2 O00748 1/20 0.52
AKR1B1 P15121 1/20 0.52
HIF1A Q16665 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
FNTA P49354 1/20 0.44
FNTB P49356 1/20 0.44
L3MBTL1 Q9Y468 3/20 0.42
MAPK1 P28482 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CTBP2 P56545 1/20 0.42
EPHX2 P34913 1/20 0.42
PLA2G10 O15496 1/20 0.42
PLA2G2A P14555 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3917561 1.00 CES1 (0.52) CES1CES2AKR1B1HIF1AMEN1
SCHEMBL11564900 0.86 CES1 (0.50) CES1CES2AKR1B1HIF1AMEN1
SCHEMBL11564897 0.86 CES1 (0.50) CES1CES2AKR1B1HIF1AMEN1
SCHEMBL20954638 0.84 CES1 (0.48) CES1CES2AKR1B1HIF1AMEN1
SCHEMBL5644461 0.82 SMN1; SMN2 (0.47) KMT2ACYP3A4CYP2C9ALDH1A1CTBP2
SCHEMBL4317702 0.82 PDPK1 (0.47) MEN1KMT2ACYP3A4CYP2C9L3MBTL1
SCHEMBL5644457 0.82 SMN1; SMN2 (0.47) KMT2ACYP3A4CYP2C9ALDH1A1CTBP2
SCHEMBL29089424 0.82 HDAC1 (0.53) CES1CES2AKR1B1HIF1AMEN1
SCHEMBL4317706 0.82 PDPK1 (0.47) MEN1KMT2ACYP3A4CYP2C9L3MBTL1
SCHEMBL4325304 0.82 SMN1; SMN2 (0.47) KMT2ACYP3A4CYP2C9ALDH1A1CTBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0326389-B1 Process for preparing 4-hydroxypyrimidine UBE INDUSTRIES (JP) 1996-09-11 EP claimed
CN-107721917-A A kind of green synthesis method of polysubstituted nicotinate compound 河南理工大学 2018-02-23 CN disclosed
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE GAUDINO JOHN 2011-03-03 US disclosed
EP-2032538-A2 QUINOLINE COMPOUNDS AND METHODS OF USE Array Biopharma, Inc. (US) 2009-03-11 EP disclosed
WO-2007146824-A2 QUINOLINE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2007-12-21 WO disclosed
US-20070037807-A1 Pyridine compounds as inhibitors of dipeptidyl peptidase IV TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-02-15 US disclosed
EP-1678138-A1 PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV Takeda Pharmaceutical Company Limited (JP) 2006-07-12 EP disclosed
WO-2005042488-A1 PYRIDINE COMPOUNDS AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037807-A1 Pyridine compounds as inhibitors of dipeptidyl peptidase IV DPP4, DPP3, PEPD CES1 206/4885CES2 875/4885AKR1B1 395/4885
US-20110053931-A1 QUINOLINE COMPOUNDS AND METHODS OF USE TK1, ABL1, ROR1 CES1 1252/4885CES2 1622/4885AKR1B1 387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.